Skip to Content

New Additions to for 2017

We update the database on a regular cycle. The following new drug information has been added this year:

Showing additions for:

Mar 24, 2017 - Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC).

Mar 22, 2017 - Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

Mar 13, 2017 - Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor indicated for the treatment of postmenopausal women with HR+/HER2- metastatic breast cancer.

Mar 2, 2017 - Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.

Feb 28, 2017 - Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.

Jan 25, 2017 - Trulance (plecanatide) is a uroguanylin analog for the treatment of chronic idiopathic constipation.

Jan 23, 2017 - Rhofade (oxymetazoline hydrochloride) cream is a topical vasoconstrictor for the treatment of facial erythema associated with rosacea.

Browse additions by year: